Depression-like phenotype following chronic CB1 receptor antagonism

The rat brain in stereotaxic coordinates

Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959 · see citing works

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · see citing works

Drug treatments for obesity: orlistat, sibutramine, and rimonabant

Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · see citing works

Endocannabinoid control of food intake and energy balance

Marzo, V. D., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 746 · see citing works

Involvement of CB1 cannabinoid receptors in emotional behaviour

Martín, M., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 507 · see citing works

Cytokines as mediators of depression: what can we learn from animal studies?

Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459 · see citing works

Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis

Taliaz, D., Stall, N., Dar, D. E., & Zangen, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.67 · Cited by 454 · see citing works

Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex

Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325 · see citing works

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat

Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. Á., Carrera, M. R. A., & de Fonseca, F. R. (1997) · Neuroreport · doi:10.1097/00001756-199701200-00023 · Cited by 306 · see citing works

Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonist

Rinaldi, M. L., Barth, F., Héaulme, M., Alonso, R., Shire, D. J., Congy, C., Soubrié, P., Brelière, J.-C., & Fur, G. L. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00174-5 · Cited by 303 · see citing works

Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains

Bekris, S., Antoniou, K., Daskas, S., & Papadopoulou-Daifoti, Z. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.01.005 · Cited by 281 · see citing works

Peripheral mechanisms of pain and analgesia

Stein, C., Clark, J. D., Oh, U., Vasko, M. R., Wilcox, G. L., Overland, A. C., Vanderah, T. W., & Spencer, R. H. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.017 · Cited by 268 · see citing works

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253 · see citing works

Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia

Grippo, A. J., Francis, J., Beltz, T. G., Felder, R. B., & Johnson, A. K. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.02.011 · Cited by 233 · see citing works

The obesity pipeline: current strategies in the development of anti-obesity drugs

Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 212 · see citing works

Behavioral and cardiovascular changes in the chronic mild stress model of depression

Grippo, A. J., Beltz, T. G., & Johnson, A. K. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00050-7 · Cited by 198 · see citing works

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

Janero, D. R., & Makriyannis, A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902736568 · Cited by 186 · see citing works

Differentiating antidepressants of the future: Efficacy and safety

Rosenzweig-Lipson, S. J., Beyer, C. E., Hughes, Z. A., Khawaja, X. Z., Rajarao, S. J. R., Malberg, J. E., Rahman, Z. U., Ring, R. H., & Schechter, L. E. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.002 · Cited by 182 · see citing works

Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs

Malberg, J., & Schechter, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382223 · Cited by 167 · see citing works

The Effects of Chronic Fluoxetine Treatment on Chronic Mild Stress-Induced Cardiovascular Changes and Anhedonia

Grippo, A. J., Beltz, T. G., Weiss, R. M., & Johnson, A. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.010 · Cited by 167 · see citing works

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

Huestis, M. A., Boyd, S. J., Heishman, S. J., Preston, K. L., BONNET, D., Fur, G. L., & Gorelick, D. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0861-5 · Cited by 166 · see citing works

The Need for Bold Action to Prevent Adolescent Obesity

Brownell, K. D., Schwartz, M. B., Puhl, R. M., Henderson, K. E., & Harris, J. L. (2009) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.03.004 · Cited by 140 · see citing works

The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food

Melis, T., Succu, S., Sanna, F., Boi, A., Argiolas, A., & Melis, M. R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.04.012 · Cited by 138 · see citing works

Chronic mild stress decreases survival, but not proliferation, of new-born cells in adult rat hippocampus

Lee, K. J., Kim, S.-J., Kim, S.-W., Choi, S.-H., Shin, Y.-C., Park, S.-H., Moon, B., Cho, E., Lee, M.-S., Choi, S.-H., et al. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.6 · Cited by 136 · see citing works

Activation of endocannabinoid transmission induces antidepressant-like effects in rats.

Adamczyk, P., Gołda, A., McCreary, A. C., Filip, M., & Przegaliński, E. (2008) · PubMed · Cited by 123 · see citing works

Serotonin Evokes Endocannabinoid Release and Retrogradely Suppresses Excitatory Synapses

Best, A. R., & Regehr, W. G. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0678-08.2008 · Cited by 122 · see citing works

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

Rosenzweig-Lipson, S. J., Sabb, A. L., Stack, G., Mitchell, P., Lucki, I., Malberg, J. E., Grauer, S. M., Brennan, J. A., Cryan, J. F., Rizzo, S. J. S., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0710-6 · Cited by 102 · see citing works

Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models

Bambico, F. R., Duranti, A., Tontini, A., Tarzia, G., & Gobbi, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168029 · Cited by 91 · see citing works

Depression and anxiety with rimonabant

Mitchell, P. B., & Morris, M. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61705-x · Cited by 89 · see citing works

The cannabinoid CB 1 receptor and the endocannabinoid anandamide: possible antidepressant targets

Bambico, F. R., & Gobbi, G. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1347 · Cited by 80 · see citing works

BDNF regulates neuronal sensitivity to endocannabinoids

Maison, P., Walker, D. J., Walsh, F. S., Williams, G. H., & Doherty, P. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.011 · Cited by 69 · see citing works

[Validation of an animal model of anhedonia, a major symptom of depression].

Moreau, J. (1997) · PubMed · Cited by 67 · see citing works

Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity

Patel, P. N., & Pathak, R. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/060258 · Cited by 63 · see citing works

Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Δ9-tetrahydrocannabinol

Buchweitz, J. P., Karmaus, P. W. F., Williams, K. J., Harkema, J. R., & Kaminski, N. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907618 · Cited by 55 · see citing works

Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain

Marchalant, Y., Brothers, H. M., & Wenk, G. L. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.62 · Cited by 54 · see citing works

Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse

Balu, D. T., Hodes, G. E., Hill, T. E., Ho, N., Rahman, Z. U., Bender, C. N., Ring, R. H., Dwyer, J. M., Rosenzweig-Lipson, S. J., Hughes, Z. A., et al. (2008) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2008.12.002 · Cited by 51 · see citing works

Die Bedeutung des TNF-α-Systems für Erkrankungen des Gehirns

Himmerich, H., Berthold‐Losleben, M., & Pollmächer, T. (2009) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0028-1109420 · Cited by 49 · see citing works

Benefits and risks of homoeopathy

Goldacre, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61706-1 · Cited by 39 · see citing works

Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry

McCulloch, M., Zhou, X., Xu, Y., Brunell, S. C., & SPEAR, L. P. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.01.020 · Cited by 22 · see citing works

Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats

Ward, S. J., Lefever, T. W., Rawls, S. M., Whiteside, G. T., & Walker, E. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1592-6 · Cited by 15 · see citing works

TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment

Li, Y., Luikart, B. W., Birnbaum, S. G., Chen, J., Kwon, C., Kernie, S. G., Bassel‐Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.021 · Cited by 8 · see citing works

Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship

McPartland, J. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005092 · Cited by 7 · see citing works

Escitalopram has potent and rapid effect in a chronic mild stress model of depression in rats

Papp, M., & Sánchez, C. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80243-1 · Cited by 2 · see citing works

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study

Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.61 · Cited by 361 · see citing works

Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks

Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256 · see citing works

Cannabinoid CB1 receptors in the amygdalar cholecystokinin glutamatergic afferents to nucleus accumbens modulate depressive-like behavior

Shen, C.-J., Zheng, D., Li, K., Yang, J., Pan, H., Yu, X.-D., Fu, J., Zhu, Y., Sun, Q.-X., Tang, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0299-9 · Cited by 223 · see citing works

Neuroimmunological effects of physical exercise in depression

Eyre, H. A., & Baune, B. T. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.09.015 · Cited by 188 · see citing works

Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors

Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 180 · see citing works

CB1 receptor-deficient mice as a model for depression

Valverde, O., & Torrens, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.031 · Cited by 153 · see citing works

Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward

Volkow, N. D., Hampson, A. J., & Baler, R. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104615 · Cited by 150 · see citing works

Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives

Strekalova, T. V., Liu, Y., Kiselev, D., Khairuddin, S., Chiu, J. L. Y., Lam, J., Chan, Y., Pavlov, D., Proshin, A. T., Lesch, K., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05982-w · Cited by 146 · see citing works

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity

Brents, L. K., Gallus‐Zawada, A. E., Radominska-p, A., Vasiljevik, T., Prisinzano, T. E., Fantegrossi, W. E., Moran, J. H., & Prather, P. L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.004 · Cited by 143 · see citing works

The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

Blázquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón, D., Sendtner, M., Timmusk, T., Lutz, B., Galve‐Roperh, I., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.11 · Cited by 141 · see citing works

Monoacylglycerol Lipase Inhibition Blocks Chronic Stress-Induced Depressive-Like Behaviors via Activation of mTOR Signaling

Zhong, P., Wang, W., Pan, B., Liu, X., Zhang, Z., Long, J. Z., Zhang, H., Cravatt, B. F., & Liu, Q.-S. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.24 · Cited by 137 · see citing works

Endocannabinoid System Components as Potential Biomarkers in Psychiatry

Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 134 · see citing works

Alterations in Corticolimbic Dendritic Morphology and Emotional Behavior in Cannabinoid CB1 Receptor-Deficient Mice Parallel the Effects of Chronic Stress

Hill, M. N., Hillard, C. J., & McEwen, B. S. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq280 · Cited by 127 · see citing works

A Guide to Targeting the Endocannabinoid System in Drug Design

Stasiulewicz, A., Znajdek, K., Grudzień, M. K., Pawiński, T., & Sulkowska, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082778 · Cited by 121 · see citing works

Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation

Zoppi, S., Perez‐Nievas, B. G., Madrigal, J. L. M., Manzanares, J., Leza, J. C., & García‐Bueno, B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.214 · Cited by 116 · see citing works

Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses

Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 117 · see citing works

Interleukin-1β Causes Anxiety by Interacting with the Endocannabinoid System

Rossi, S., Sacchetti, L., Napolitano, F., Chiara, V. D., Motta, C., Studer, V., Musella, A., Barbieri, F. R., Bari, M., Bernardi, G., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1515-12.2012 · Cited by 113 · see citing works

Anhedonia in depression symptomatology: appetite dysregulation and defective brain reward processing

Coccurello, R. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112041 · Cited by 106 · see citing works

The case for peripheral CB1receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

Kunos, G., & Tam, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01352.x · Cited by 111 · see citing works

The utility of animal models to evaluate novel anti‐obesity agents

Vickers, S. P., Jackson, H. C., & Cheetham, S. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01245.x · Cited by 107 · see citing works

Endocannabinoid-mediated synaptic plasticity and addiction-related behavior

Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92 · see citing works

Rutin, a Flavonoid and Principal Component of Saussurea Involucrata, Attenuates Physical Fatigue in a Forced Swimming Mouse Model

Su, K., Yu, C. Y., Chen, Y., Huang, Y., Chen, C., Wu, H., & Chen, Y. S. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8220 · Cited by 90 · see citing works

Brain CB2 Receptors: Implications for Neuropsychiatric Disorders

Roche, M., & Finn, D. P. (2010) · Pharmaceuticals · doi:10.3390/ph3082517 · Cited by 87 · see citing works

Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear

Choi, K. H., Le, T., McGuire, J. L., Xing, G., Zhang, L., Li, H., Parker, C. C., Johnson, L. R., & Ursano, R. J. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.03.021 · Cited by 83 · see citing works

Cannabinoid Receptor Genotype Moderation of the Effects of Childhood Physical Abuse on Anhedonia and Depression

Arpana Agrawal, A., Nelson, E. C., Littlefield, A. K., Bucholz, K. K., Degenhardt, L. J., Henders, A. K., Madden, P. A. F., Martin, N. G., Montgomery, G. W., Pergadia, M. L., et al. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2273 · Cited by 83 · see citing works

Cannabinoids and emotionality: a neuroanatomical perspective

McLaughlin, R. J., & Gobbi, G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.052 · Cited by 82 · see citing works

Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression

Gallego‐Landin, I., García-Baos, A., Castro‐Zavala, A., & Valverde, O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.762738 · Cited by 84 · see citing works

The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis

Navarria, A., Tamburella, A., Iannotti, F. A., Micale, V., Camillieri, G., Gozzo, L., Verde, R., Imperatore, R., Leggio, G. M., Drago, F., et al. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.014 · Cited by 82 · see citing works

Animal models to improve our understanding and treatment of suicidal behavior

Gould, T. D., Georgiou, P., Brenner, L. A., Brundin, L., Can, A., Courtet, P., Donaldson, Z. R., Dwivedi, Y., Guillaume, S., Gottesman, I. I., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.50 · Cited by 81 · see citing works

Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

Haney, M., Vallée, M., Fabre, S., Collins, S. L., Zanese, M., Campistron, G., Arout, C. A., Foltin, R. W., Cooper, Z. D., Kearney-Ramos, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02381-w · Cited by 78 · see citing works

Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness

Hillard, C. J., & Liu, Q.-S. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660735 · Cited by 79 · see citing works

The CB₁Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability

Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74 · see citing works

Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder

Neumeister, A., Seidel, J., Ragen, B., & Pietrzak, R. H. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.012 · Cited by 76 · see citing works

2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics

Bedse, G., Hill, M. N., & Patel, S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.015 · Cited by 75 · see citing works

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression

Zádor, F., Joca, S. R. L., Nagy-Grócz, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Benyhe, S., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115903 · Cited by 72 · see citing works

Endocannabinoids and Mental Disorders

Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 71 · see citing works

The phytocannabinoid, Δ9‐tetrahydrocannabivarin, can act through 5‐ HT 1 A receptors to produce antipsychotic effects

Cascio, M. G., Zamberletti, E., Marini, P., Parolaro, D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.13000 · Cited by 67 · see citing works

Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?

Boorman, E., Zajkowska, Z., Ahmed, R., Pariante, C. M., & Zunszain, P. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4105-9 · Cited by 66 · see citing works

Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability

Schurman, L. D., Wills, K. L., Segsworth, B. M., Dashney, B., Rock, E. M., Limebeer, C. L., & Parker, L. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.10.008 · Cited by 66 · see citing works

Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD

Ney, L. J., Akhurst, J., Bruno, R., Laing, P. A. F., Matthews, A. J., & Felmingham, K. L. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110118 · Cited by 61 · see citing works

Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission

Bambico, F. R., Hattan, P. R., Garant, J.-P., & Gobbi, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.006 · Cited by 61 · see citing works

Cannabinoid CB1 receptor in the modulation of stress coping behavior in mice: The role of serotonin and different forebrain neuronal subpopulations

Häring, M., Grieb, M., Monory, K., Lutz, B., & Moreira, F. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.09.002 · Cited by 59 · see citing works

Cannabinoids in depressive disorders

Poleszak, E., Wośko, S., Sławińska, K., Szopa, A., Wróbel, A., & Serefko, A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.058 · Cited by 55 · see citing works

The vital role of constitutive GPCR activity in the mesolimbic dopamine system

Meye, F. J., Ramakers, G. M. J., & Adan, R. A. H. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.130 · Cited by 55 · see citing works

Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral‐Antagonist/Inverse‐Agonist Therapies

Ward, S. J., & Raffa, R. B. (2011) · Obesity · doi:10.1038/oby.2011.69 · Cited by 50 · see citing works

Cannabinoids prevent depressive-like symptoms and alterations in BDNF expression in a rat model of PTSD

Burstein, O., Shoshan, N., Doron, R., & Akirav, I. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.026 · Cited by 51 · see citing works

Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing

Horder, J., Browning, M., Di Simplicio, M., Cowen, P. J., & Harmer, C. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111400649 · Cited by 48 · see citing works

The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism

Jenny, M., Schröcksnadel, S., Überall, F., & Fuchs, D. (2010) · Pharmaceuticals · doi:10.3390/ph3082647 · Cited by 69 · see citing works

Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis

Gentile, A., Fresegna, D., Musella, A., Sepman, H., Bullitta, S., Vito, F. D., Fantozzi, R., Usiello, A., Maccarrone, M., Mercuri, N. B., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0682-8 · Cited by 48 · see citing works

A neural circuit associated with anxiety‐like behaviors induced by chronic inflammatory pain and the anxiolytic effects of electroacupuncture

Wu, Z., Shen, Z., Xu, Y., Chen, S., Xiao, S., Ye, J., Zhang, H., Ma, X., Zhu, Y., Zhu, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14520 · Cited by 46 · see citing works

Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence

Micale, V., Tabiová, K., Kučerová, J., & Drago, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_5 · Cited by 47 · see citing works

Cannabis controversies: how genetics can inform the study of comorbidity

Arpana Agrawal, A., & Lynskey, M. T. (2014) · Addiction · doi:10.1111/add.12436 · Cited by 45 · see citing works

Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 45 · see citing works

CB1 receptors modulate affective behaviour induced by neuropathic pain

Rácz, I., Nent, E., Erxlebe, E., & Zimmer, A. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.03.005 · Cited by 43 · see citing works

Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

Navarro, D., Gasparyan, A., Navarrete, F., Torregrosa, A. B., Rubio, G., Marín, M., Acosta, G. B., García‐Gutiérrez, M. S., & Manzanares, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094764 · Cited by 45 · see citing works

Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

Bright, U., & Akirav, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105526 · Cited by 47 · see citing works

Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship

Frisardi, V., Panza, F., & Farooqui, A. A. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.04.003 · Cited by 40 · see citing works

The Endocannabinoid/Endovanilloid System and Depression

Smaga, I., Bystrowska, B., Gawliński, D., Przegaliński, E., & Filip, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140923205412 · Cited by 39 · see citing works

Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms

Amchová, P., Kučerová, J., Giugliano, V., Babinská, Z., Zanda, M. T., Scherma, M., Dušek, L., Fadda, P., Micale, V., Šulcová, A., et al. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00044 · Cited by 38 · see citing works

Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity

Zádor, F., Kocsis, D., Borsodi, A. D., & Benyhe, S. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.12.005 · Cited by 37 · see citing works

Evaluation of the potential of the phytocannabinoids, cannabidivarin ( CBDV ) and Δ9‐tetrahydrocannabivarin ( THCV ), to produce CB1 receptor inverse agonism symptoms of nausea in rats

Rock, E. M., Sticht, M. A., Duncan, M., Stott, C. G., & Parker, L. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12322 · Cited by 35 · see citing works

Behavioral assessment of rimonabant under acute and chronic conditions

Ettaro, R., Laudermilk, L. T., Clark, S. D., & Maitra, R. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112697 · Cited by 35 · see citing works

Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain

Jiang, H., Ke, B., Liu, J., Ma, G., Hai, K., Gong, D., Yang, Z., & Zhou, C. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003563 · Cited by 34 · see citing works

NESS06SM reduces body weight with an improved profile relative to SR141716A

Mastinu, A., Pira, M., Pinna, G. A., Pisu, C., Casu, M. A., Reali, R., Marcello, S., Murineddu, G., & Lazzari, P. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.001 · Cited by 32 · see citing works

Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders

Estrada, J. A., & Contreras, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200217140255 · Cited by 32 · see citing works

Gut hormones: the future of obesity treatment?

McGavigan, A. K., & Murphy, K. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04278.x · Cited by 31 · see citing works

Circulating endocannabinoids and psychological outcomes in women with PTSD

Botsford, C., Brellenthin, A. G., Cisler, J. M., Hillard, C. J., Koltyn, K. F., & Crombie, K. M. (2022) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2022.102656 · Cited by 29 · see citing works

Bipolar disorder and the endocannabinoid system

Arjmand, S., Behzadi, M., Kohlmeier, K. A., Mazhari, S., Sabahi, A., & Shabani, M. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.21 · Cited by 29 · see citing works

Cannabinoids and neuroinflammation: Therapeutic implications

Leonard, B. E., & Arıcıoğlu, F. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100463 · Cited by 28 · see citing works

Chronic Inhibition of FAAH Reduces Depressive-Like Behavior and Improves Dentate Gyrus Proliferation after Chronic Unpredictable Stress Exposure

Tejeda-Martínez, A. R., Paredes, J. M. V., Hidalgo-Franco, G. V., Pardo-González, E., Chaparro-Huerta, V., González-Castañeda, R., & Flores-Soto, M. E. (2021) · Behavioural Neurology · doi:10.1155/2021/6651492 · Cited by 28 · see citing works

Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression

Kaminitz, A., Barzilay, R., Segal‐Gavish, H., Taler, M., Offen, D., Gil‐Ad, I., Mechoulam, R., & Weizman, A. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.841993 · Cited by 27 · see citing works

Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation

de la Tremblaye, P. B., O’Neil, D. A., LaPorte, M. J., B, J. P. C. A., Beitchman, J. A., Thomas, T. C., Bondi, C. O., & Kline, A. E. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.022 · Cited by 25 · see citing works

Multiregional profiling of the brain transmembrane proteome uncovers novel regulators of depression

Li, S., Luo, H., Lou, R., Tian, C., Chen, M., Xia, L., Pan, C., Duan, X., Dang, T., Li, H. Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf0634 · Cited by 25 · see citing works

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

Janero, D. R., Lindsley, L., Vemuri, K. V., & Makriyannis, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.608063 · Cited by 25 · see citing works

Brain endocannabinoid signaling exhibits remarkable complexity

Gorzkiewicz, A., & Szemraj, J. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.012 · Cited by 24 · see citing works

N-3 PUFA improved post-menopausal depression induced by maternal separation and chronic mild stress through serotonergic pathway in rats—effect associated with lipid mediators

Choi, J.-E., Borkowski, K., Newman, J. W. I., & Park, Y. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108599 · Cited by 23 · see citing works

Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner

Zádor, F., Lénárt, N., Csibrány, B., Sántha, M., Molnar, M. F., Tuka, B., Samavati, R., Klivènyi, P., Vécsei, L., Marton, A., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.008 · Cited by 21 · see citing works

Effects of CB1 receptor antagonism and stress exposures in adolescence on socioemotional behaviours, neuroendocrine stress responses, and expression of relevant proteins in the hippocampus and prefrontal cortex in rats

Simone, J. J., Baumbach, J. L., & McCormick, C. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.029 · Cited by 21 · see citing works

How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?

Vaseghi, S., Nasehi, M., & Zarrindast, M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.018 · Cited by 21 · see citing works

Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach

Foll, B. L., Pushparaj, A. P., Pryslawsky, Y., Forget, B., Vemuri, K. V., Makriyannis, A., & Trigo, J. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.009 · Cited by 20 · see citing works

Further evidence of anxiety- and depression-like behavior for total genetic ablation of cannabinoid receptor type 1

Soriano, D., Brusco, A., & Caltana, L. R. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113007 · Cited by 18 · see citing works

Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors

Zádor, F., Ötvös, F., Benyhe, S., Zimmer, A., & Páldy, E. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.015 · Cited by 20 · see citing works

Unexpected short- and long-term effects of chronic adolescent HU-210 exposure on emotional behavior

Farinha‐Ferreira, M., Rei, N., Fonseca‐Gomes, J., Miranda‐Lourenço, C., Serrão, P., Vaz, S. H., Gomes, J. I., Martins, V., Pereira, B. D. A., & Sebastião, A. M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109155 · Cited by 19 · see citing works

Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders

Coelho, A. A., Bastos, S., Gobira, P. H., & Lisboa, S. F. D. S. (2023) · Neuronal Signaling · doi:10.1042/ns20220034 · Cited by 22 · see citing works

Discovery of a CB2 and 5-HT1A receptor dual agonist for the treatment of depression and anxiety.

Yang, W., Gong, X.-B., Sun, H.-G., Wu, C., Suo, J., Ji, J., Jiang, X.-R., Shen, J., He, Y., & Aisa, H. (2023) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2023.116048 · Cited by 17 · see citing works

The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

Davis, M. P., Behm, B., Mehta, Z. Y., & Fernandez, C. (2019) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909119850807 · Cited by 19 · see citing works

URB597 ameliorates the deleterious effects induced by binge alcohol consumption in adolescent rats

Bellozi, P. M. Q., Pelição, R., dos Santos, M. C., Lima, I. V. D. A., Saliba, S. W., Vieira, É. L. M., Campos, A. C., Teixeira, A. L., de Oliveira, A. C. P., Nakamura-Palacios, E. M., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134408 · Cited by 18 · see citing works

The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health

Amatriain‐Fernández, S., Budde, H., Gronwald, T., Quiroga, C., Carreón, C., Viana-Torre, G., Yamamoto, T., Imperatori, C., Machado, S. E. D. C., & Murillo‐Rodríguez, E. (2020) · Current Neuropharmacology · doi:10.2174/1570159x19666201218112748 · Cited by 17 · see citing works

Chronic exposure to cannabinoids before an emotional trauma may have negative effects on emotional function

Sbarski, B., & Akirav, I. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.05.008 · Cited by 17 · see citing works

α-Tocopherol and α-tocopheryl phosphate interact with the cannabinoid system in the rodent hippocampus

Crouzin, N., Ferreira, M. D. J., Cohen‐Solal, C., M’Kadmi, C., Bernad, N., Martínez, J., Barbanel, G., Vignes, M., & Guiramand, J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.07.012 · Cited by 17 · see citing works

Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD

Murkar, A., Kendzerska, T., Shlik, J., Quilty, L. C., Saad, M., & Robillard, R. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04185-7 · Cited by 17 · see citing works

Metabolic Profiling of CB1 Neutral Antagonists

Seltzman, H. H., Maitra, R., Bortoff, K., Henson, J., Reggio, P. H., Wesley, D., & Tam, J. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.06.025 · Cited by 16 · see citing works

A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates

Hjorth, S., Karlsson, C., Jučaitė, A., Varnäs, K., Hamrén, U. W., Johnström, P., Gulyás, B. Z., Donohue, S. R., Pike, V. W., Halldin, C., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.002 · Cited by 16 · see citing works

Endocannabinoids and Stress Resilience: Is Deficiency Sufficient to Promote Vulnerability?

Hill, M. N., & Lee, F. S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2099 · Cited by 15 · see citing works

AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects

Soler‐Cedeño, O., Alton, H., Bi, G., Linz, E., Ji, L., Makriyannis, A., & Xi, Z. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01861-y · Cited by 15 · see citing works

Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice

Poleszak, E., Wośko, S., Sławińska, K., Wyska, E., Szopa, A., Świąder, K., Wróbel, A., Doboszewska, U., Właź, P., Właź, A., et al. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172833 · Cited by 14 · see citing works

Nutraceutical eicosapentaenoic acid in treatment-resistant depression: The psychoneuroimmunity and clinical implications

Chang, J. P., Iqbal, A. Z., Do, Q. L., Yaseen, M., Wu, S., Malau, I. A., Zailani, H., & Su, K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107857 · Cited by 13 · see citing works

Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor

McLaughlin, P. J., Jagielo-Miller, J. E., Plyler, E. S., Schutte, K., Vemuri, K. V., & Makriyannis, A. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4548-2 · Cited by 13 · see citing works

The molecular interplay between endocannabinoid and neurotrophin signals in the nervous system and beyond

Keimpema, E., Hökfelt, T. G. M., Harkany, T., & Doherty, P. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12431 · Cited by 13 · see citing works

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice

Patel, K. N., Joharapurkar, A. A., PATEL, V. G., Kshirsagar, S. G., Bahekar, R. H., Srivastava, B. K., & Jain, M. R. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0310 · Cited by 13 · see citing works

Antidepressant-Like Activity of Cannabinoid Type-1 Receptor Antagonist, Rimonabant: Behavioural Investigation in Animal Model of Depression

Mahesh, R., Sharma, P., Gautam, B., Bhatt, S., & Pandey, D. K. (2010) · International Journal of Pharma and Bio Sciences · Cited by 1 · see citing works

The psychiatric side-effects of rimonabant

Moreira, F. A., & Crippa, J. A. S. (2009) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462009000200012 · Cited by 235 · see citing works

Behavioral assessment of rimonabant under acute and chronic conditions

Ettaro, R., Laudermilk, L. T., Clark, S. D., & Maitra, R. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112697 · Cited by 35 · see citing works

MODEL OF DEPRESSION

Mahesh, R., Sharma, P., Gautam, B., & Pandey, D. K. (2011)

The neuropsychopharmacology of rimonabant

Horder, J. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)